Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-06), Shenzhenlubris Pharmaceuticals Co's Beta is 0.3862.
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Shenzhenlubris Pharmaceuticals Co Beta Related Terms
Shenzhenlubris Pharmaceuticals Co Beta Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhenlubris Pharmaceuticals Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhenlubris Pharmaceuticals Co Beta vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Beta distribution charts can be found below:
* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Beta falls into.
Shenzhenlubris Pharmaceuticals Co Beta Calculation
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) has a Beta of 0.3862 as of Aug. 06, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Shenzhenlubris Pharmaceuticals Co and its competitors.
Is Shenzhenlubris Pharmaceuticals Co's Beta too high?
Shenzhenlubris Pharmaceuticals Co's current Beta is 0.3862. Overall, Shenzhenlubris Pharmaceuticals Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhenlubris Pharmaceuticals Co's Beta compare to ZTS?
Shenzhenlubris Pharmaceuticals Co's Beta of 0.3862 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Shenzhenlubris Pharmaceuticals Co and its competitors. Shenzhenlubris Pharmaceuticals Co's current Beta is 0.3862. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhenlubris Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co (SZSE:002294) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥44.01, compared to a current price of ¥33.85 — trading 23.1% below its estimated fair value. The current Beta is 0.3862. Shenzhenlubris Pharmaceuticals Co's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Shenzhenlubris Pharmaceuticals Co (SZSE:002294), the current Beta is 0.3862 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhenlubris Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥33.85 is trading 23.1% below its estimated GF Value™ of ¥44.01.
GuruFocus considers Shenzhenlubris Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SZSE:002294:
Beta: 0.3862
GF Value™: ¥44.01 vs. price of ¥33.85 (23.1% below fair value)
No single metric tells the full story. See the SZSE:002294 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
82GF Score
Get the complete analysis for SZSE:002294
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002294 has been successfully added to your 
